gemfibrozil has been researched along with Hyperlipidemia, Familial Combined in 24 studies
Hyperlipidemia, Familial Combined: A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the lipid-regulating effects of gemfibrozil and lovastatin in 30 patients with familial combined hyperlipidemia (FCHL) in a randomized, double-blind, placebo-controlled crossover study including 8-week courses of one drug followed by a washout period and a crossover phase to the alternate drug." | 9.09 | Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. ( Casals, E; Hernández, G; Laguna, JC; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Sol, JM; Vázquez, M; Zambón, D, 1999) |
| "We evaluated in a double-blind, placebo-controlled, randomized trial of 45 well-defined patients with familial combined hyperlipidemia, the effect of gemfibrozil (1,200 mg/day) or simvastatin (20 mg/day) on apolipoprotein-B (apo-B)-containing lipoproteins, low-density lipoprotein (LDL) subfraction profile, and LDL oxidizability." | 9.08 | Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. ( Bredie, SJ; de Bruin, TW; Demacker, PN; Kastelein, JJ; Stalenhoef, AF, 1995) |
| "A randomized double blind, placebo-controlled crossover design was used to determine the efficacy of gemfibrozil and clofibrate in the treatment of familial combined hyperlipidemia and to determine which one of these agents would be more effective." | 9.06 | Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. ( Frohlich, J; Hayden, M; Rabkin, SW, 1988) |
| "The purpose of the present study was to assess the effect of gemfibrozil on 12 independent coronary heart disease risk factors in patients with primary combined hyperlipidaemia." | 7.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| " We compared the lipid-regulating effects of gemfibrozil and lovastatin in 30 patients with familial combined hyperlipidemia (FCHL) in a randomized, double-blind, placebo-controlled crossover study including 8-week courses of one drug followed by a washout period and a crossover phase to the alternate drug." | 5.09 | Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. ( Casals, E; Hernández, G; Laguna, JC; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Sol, JM; Vázquez, M; Zambón, D, 1999) |
| "We evaluated in a double-blind, placebo-controlled, randomized trial of 45 well-defined patients with familial combined hyperlipidemia, the effect of gemfibrozil (1,200 mg/day) or simvastatin (20 mg/day) on apolipoprotein-B (apo-B)-containing lipoproteins, low-density lipoprotein (LDL) subfraction profile, and LDL oxidizability." | 5.08 | Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. ( Bredie, SJ; de Bruin, TW; Demacker, PN; Kastelein, JJ; Stalenhoef, AF, 1995) |
| "A randomized double blind, placebo-controlled crossover design was used to determine the efficacy of gemfibrozil and clofibrate in the treatment of familial combined hyperlipidemia and to determine which one of these agents would be more effective." | 5.06 | Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. ( Frohlich, J; Hayden, M; Rabkin, SW, 1988) |
| "To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial combined hyperlipidemia." | 5.06 | Combination drug therapy for familial combined hyperlipidemia. ( Bilheimer, DW; East, C; Grundy, SM, 1988) |
| "The purpose of the present study was to assess the effect of gemfibrozil on 12 independent coronary heart disease risk factors in patients with primary combined hyperlipidaemia." | 3.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| "Atorvastatin monotherapy has a better effect on LDL-C and apoprotein B than statin-fibrate combinations, but a lesser effect on HDL-C, TG and in the case of ciprofibrate combinations, fibrinogen." | 2.70 | Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. ( Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN, 2002) |
| "Lovastatin treatment had no effect on the lipid and protein composition, the fatty acid profile, or the vitamin E content of either VLDL or LDL; likewise, lipoprotein oxidation markers (Cu-induced conjugated dienes, thiobarbituric acid reactive substances formation, and lysine residues) were similar before and after lovastatin treatment." | 2.69 | Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. ( Adzet, T; Hernández, Y; Laguna, JC; Merlos, M; Ros, E; Vázquez, M; Zambón, D, 1998) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " Physical and laboratory investigations for adverse effects were performed every month for the first 3 months and every 3 months thereafter." | 2.68 | Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. ( Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA, 1997) |
| "Gemfibrozil treatment was associated with a rise in the relative biliary concentration of cholesterol from 5." | 2.67 | Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids. ( Angelin, B; Berglund, L; Ericsson, S; Lindmark, M; Odman, B, 1991) |
| "Gemfibrozil was more effective in reducing triglyceride levels and in increasing high-density lipoprotein (HDL) cholesterol in both strata, although increases in HDL/LDL cholesterol ratios were greater with lovastatin." | 2.67 | Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study. ( Helve, E; Ojala, JP; Tikkanen, MJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 17 (70.83) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Superko, HR | 1 |
| Garrett, BC | 1 |
| King, SB | 1 |
| Momary, KM | 1 |
| Chronos, NA | 1 |
| Wood, PD | 1 |
| Ooi, TC | 1 |
| Cousins, M | 1 |
| Ooi, DS | 1 |
| Nakajima, K | 1 |
| Edwards, AL | 1 |
| Bertolotti, M | 1 |
| Concari, M | 1 |
| Loria, P | 1 |
| Abate, N | 1 |
| Pinetti, A | 1 |
| Guicciardi, ME | 1 |
| Carulli, N | 1 |
| Bröijersén, A | 1 |
| Eriksson, M | 1 |
| Angelin, B | 2 |
| Hjemdahl, P | 1 |
| Athyros, VG | 4 |
| Papageorgiou, AA | 4 |
| Avramidis, MJ | 1 |
| Kontopoulos, AG | 4 |
| Castro Cabezas, M | 1 |
| Erkelens, DW | 1 |
| Kock, LA | 1 |
| De Bruin, TW | 3 |
| Bredie, SJ | 2 |
| Demacker, PN | 1 |
| Kastelein, JJ | 2 |
| Stalenhoef, AF | 2 |
| Hokanson, JE | 1 |
| Austin, MA | 1 |
| Zambon, A | 1 |
| Brunzell, JD | 1 |
| Bruckert, E | 2 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Westerveld, HT | 1 |
| Knipscheer, HC | 1 |
| Nestel, P | 1 |
| Simons, L | 1 |
| Barter, P | 1 |
| Clifton, P | 1 |
| Colquhoun, D | 1 |
| Hamilton-Craig, I | 1 |
| Sikaris, K | 1 |
| Sullivan, D | 1 |
| Perreault, S | 1 |
| Hamilton, VH | 1 |
| Lavoie, F | 1 |
| Grover, S | 1 |
| Hatzikonstandinou, HA | 1 |
| Didangelos, TP | 1 |
| Carina, MV | 1 |
| Kranitsas, DF | 1 |
| Vázquez, M | 2 |
| Zambón, D | 2 |
| Hernández, Y | 1 |
| Adzet, T | 1 |
| Merlos, M | 1 |
| Ros, E | 2 |
| Laguna, JC | 2 |
| Rodriguez-Villar, C | 1 |
| Sanllehy, C | 1 |
| Casals, E | 1 |
| Sol, JM | 1 |
| Hernández, G | 1 |
| Athyrou, VV | 1 |
| Demitriadis, DS | 1 |
| Pehlivanidis, AN | 1 |
| Odman, B | 1 |
| Ericsson, S | 1 |
| Lindmark, M | 1 |
| Berglund, L | 1 |
| Ojala, JP | 1 |
| Helve, E | 1 |
| Tikkanen, MJ | 1 |
| Varthakavi, P | 1 |
| Turakhia, DP | 1 |
| Sharma, S | 1 |
| Salgaonkar, DS | 1 |
| Nihalani, KD | 1 |
| Joshi, VR | 1 |
| Rabkin, SW | 1 |
| Hayden, M | 1 |
| Frohlich, J | 1 |
| East, C | 1 |
| Bilheimer, DW | 1 |
| Grundy, SM | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313] | 450 participants (Actual) | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gemfibrozil and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
[Treatment of familial combined hyperlipidemia].
Topics: Clinical Protocols; Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Comb | 1997 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
16 trials available for gemfibrozil and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Female; Ge | 2009 |
Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.
Topics: Adult; Aged; Cross-Over Studies; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Male; Middl | 1995 |
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Topics: Adult; Apolipoproteins B; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial | 1995 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Cholesterol; Double-Blind Method; | 1996 |
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibro | 1997 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Thera | 1997 |
Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
Topics: Double-Blind Method; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; L | 1998 |
Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil | 1999 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibro | 2002 |
Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids.
Topics: Adult; Aged; Bile; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Gemfibrozil | 1991 |
Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
Topics: Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Hum | 1990 |
Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as To | 1988 |
Combination drug therapy for familial combined hyperlipidemia.
Topics: Adult; Cholelithiasis; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipi | 1988 |
6 other studies available for gemfibrozil and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia.
Topics: Cholesterol; Dietary Fats; Diterpenes; Fasting; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipid | 2004 |
Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans.
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Gemfibrozil; Humans; Hyper | 1995 |
Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
Topics: Coronary Disease; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lipids; Male; Midd | 1995 |
Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Child; Cholesterol; Drug | 1994 |
Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.
Topics: Adult; Aged; Cholesterol, LDL; Densitometry; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial C | 1993 |
Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Com | 1990 |